DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 Listed Suppliers

1 API Suppliers
1 Listed Suppliers

DEVELOPMENTS

14 Drugs in Development

14 Drugs in Development

DIGITAL CONTENT

1 DATA COMPILATION #PharmaFlow, 33 NEWS #PharmaBuzz

media
1 DATA COMPILATION #PharmaFlow
33 NEWS #PharmaBuzz

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

14DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1092364-38-9, Hm781-36b, Nov120101, Unii-oei6oou6ik, Poziotinib [inn], Nov-120101

Molecular Formula

C₂₃H₂₁Cl₂FN₄O₃

Molecular Weight

491.3 g/mol

InChI Key

LPFWVDIFUFFKJU-UHFFFAOYSA-N

FDA UNII

OEI6OOU6IK

Poziotinib is an orally bioavailable, quinazoline-based, irreversible pan-epidermal growth factor receptor (EGFR or HER) inhibitor, with potential antineoplastic activity. Upon oral administration, poziotinib inhibits EGFR (HER1 or ErbB1), HER2 and HER4, thereby inhibiting proliferation of tumor cells in which these receptors are overexpressed and/or mutated. EGFRs, cell surface receptor tyrosine kinases upregulated or mutated in a variety of cancer cell types, play key roles in cellular proliferation and survival.

1 2D Structure

Poziotinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one

2.1.2 InChI

InChI=1S/C23H21Cl2FN4O3/c1-3-20(31)30-8-6-13(7-9-30)33-19-10-14-17(11-18(19)32-2)27-12-28-23(14)29-16-5-4-15(24)21(25)22(16)26/h3-5,10-13H,1,6-9H2,2H3,(H,27,28,29)

2.1.3 InChI Key

LPFWVDIFUFFKJU-UHFFFAOYSA-N

2.1.4 Canonical SMILES

COC1=C(C=C2C(=C1)N=CN=C2NC3=C(C(=C(C=C3)Cl)Cl)F)OC4CCN(CC4)C(=O)C=C

2.2 Other Identifiers

2.2.1 UNII

OEI6OOU6IK

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Hm781-36

2. Hm781-36b

2.3.2 Depositor-Supplied Synonyms

1. 1092364-38-9

2. Hm781-36b

3. Nov120101

4. Unii-oei6oou6ik

5. Poziotinib [inn]

6. Nov-120101

7. Hm-781-36b

8. Poziotinib [usan]

9. 1-[4-[4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl]oxypiperidin-1-yl]prop-2-en-1-one

10. 1-(4-((4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxyquinazolin-6-yl)oxy)piperidin-1-yl)prop-2-en-1-one

11. Oei6oou6ik

12. Hm-781-36

13. Nov-1201

14. Mfcd28044290

15. Hm 781-36b

16. 1-[4-[[4-[(3,4-dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-2-propen-1-one

17. 2-propen-1-one, 1-[4-[[4-[(3,4-dichloro-2-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]oxy]-1-piperidinyl]-

18. 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one

19. 1-[4-({4-[(3,4-dichloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}oxy)piperidin-1-yl]prop-2-en-1-one

20. 2-propen-1-one, 1-(4-((4-((3,4-dichloro-2-fluorophenyl)amino)-7-methoxy-6-quinazolinyl)oxy)-1-piperidinyl)-

21. Hm-78136b

22. Poziotinib [who-dd]

23. C23h21cl2fn4o3

24. Poziotinib (hm781-36b)

25. Gtpl7903

26. Schembl3391764

27. Chembl3545154

28. Dtxsid80148853

29. Ex-a528

30. Hms3673k03

31. Amy24248

32. Bcp08270

33. Who 9736

34. Bdbm50468247

35. Nsc783296

36. Nsc800856

37. S7358

38. Zinc95930125

39. Akos026674078

40. Ccg-264748

41. Cs-3942

42. Db12114

43. Nov 120101

44. Nsc-783296

45. Nsc-800856

46. Sb16882

47. Ncgc00386427-01

48. Ncgc00386427-02

49. Ac-29021

50. As-74851

51. Bp161454

52. Da-47945

53. Hy-15730

54. Sy235762

55. Hm 781-36

56. Ft-0752903

57. A13044

58. J-690026

59. Q27088426

60. 1-(4-((4-(3,4-dichloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl)oxy(piperidin-1-yl)prop-2-en-1-one

61. 1-[4-[4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazoline-6-yloxy]-1-piperidinyl]-2-propene-1-one

2.4 Create Date

2009-01-19

3 Chemical and Physical Properties

Molecular Formula	C₂₃H₂₁Cl₂FN₄O₃
Molecular Weight	491.3 g/mol
XLogP3	5.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	6
Exact Mass	490.0974741 g/mol
Monoisotopic Mass	490.0974741 g/mol
Topological Polar Surface Area	76.6 Å²
Heavy Atom Count	33
Formal Charge	0
Complexity	684
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1